Hormone Replacement Therapy (HRT)
ID | RM186 |
---|---|
Version | 1.0.1 |
Type | Roadmap Item |
Frameworks |
Title | Hormone Replacement Therapy (HRT) |
---|---|
Description | GP Clinical Systems in England to generate a separate prescription for each Hormone Replacement Therapy (HRT) medication for the treatment of menopause symptoms. |
Date Added | May 15, 2023 |
Standards and Capabilities | Prescribing |
Change Route | Managed Capacity - Minor |
Change Type | Uplift |
Status | Closed |
Publication Date | Dec 8, 2023 |
Effective Date | Jul 1, 2024 |
Incentives / Funding | Yes |
Incentive / Funding Dates | Suppliers will be paid the lesser of: (a) the Supplier’s costs in meeting the requirement; or (b) £50,000 the “Incentive Payment” The Supplier shall provide to the Authority a detailed breakdown of its costs in meeting the requirement and the Authority shall confirm its acceptance of these costs prior to it commencing with the requirement. The Incentive Payment will be payable only if the Supplier shall complete the requirement to such an extent that it is ready for and has been submitted to the Authority for assurance by the 31st of March 2024 |
Payment Rules | As above |
Background
The Government has committed to reduce the costs of Hormone Replacement Therapy (HRT) through a new bespoke HRT pre-payment certificate which was introduced on 1st April 2023. The Department of Health and Social Care (DHSC) consulted with the representative bodies for general practitioners and pharmacists (the General Practitioners Committee England and Pharmaceutical Services Negotiating Committee) regarding the introduction of a new HRT pre-payment certificate for the treatment of menopause, and its potential impact on existing processes.
In order to effectively introduce the HRT pre-payment certificate, it is necessary to prescribe each licensed HRT medication individually, as defined in regulation 56 of the GMS Regulations. This ensures separation from any other medications prescribed simultaneously (HRT PPC guidance | NHSBSA).
To support General Practices in creating separate prescriptions for each item listed in the Part XVI – Notes on Charges of the Drug Tariff, changes need to be made to GP Clinical Systems so that separate prescriptions are automatically generated.
Outline Plan
All Foundation Suppliers must be compliant against this specification by the Effective Date. Prior to going live Suppliers must have completed the Solution Assurance by NHSE.
Summary of Change
Prescribing: MUST Epic added |
E00623 - separate prescription for licenced Hormone Replacement Therapy (HRT) medication for the treatment of menopause symptomsAs a Health or Care Professional I want to create a separate prescription for each prescribed licenced HRT medication for the treatment of menopause symptoms So that each licenced HRT medication for the treatment of menopause is created on a separate prescription Acceptance criterion 1: separate prescription for each licenced Hormone Replacement Therapy (HRT) medication for the treatment of menopause symptomsGiven the Health or Care Professional is permitted to create prescriptions When the Health or Care Professional selects to create a prescription for multiple prescribed medications And any of the prescribed medications are licenced HRT medication for the treatment of menopause symptoms Then a separate prescription is created for each licenced HRT medication for the treatment of menopause symptoms And another prescription is created for all other medications E00623 - Additional Implementation DetailsSolutions MUST comply with the following when implementing this Epic:
E00623 - Supporting Information
|
Full Specification
Prescribing v2.0.0
Assurance Approach
Suppliers will be asked to submit video evidence of test scenarios
Suppliers will be asked to provide evidence to the NHSE EPS Clinical Team on the process of UUID’s and tokens
Suppliers will be asked to provide a statement on how the system will handle certain scenarios. (e.g. bulk signing)
Suppliers will be asked to provide a change request once the test scenarios are reviewed to effect changes in the Live environment
No assurance will be required from CSG or clinical drop in
Assurance test plans will be provided by the EPS Clinical Team